The ASH Dash continues apace!

Over the last decade CAR-T cell therapy has revolutionised the treatment landscape for relapsed/refractory multiple myeloma (RRMM), offering a lifeline to patients with few remaining options.

These engineered immune cells have demonstrated remarkable activity although their progress has also revealed a complex interplay of benefits and risks, which continue to evolve with longer follow up data and real world use.

As the field matures, new insights from clinical trials shape our understanding of these therapies and also serve to highlight critical distinctions between products.  By delving into these details, we can identify patterns, anticipate challenges, and explore opportunities to improve outcomes for patients.

There’s also the excitement of the proverbial ‘new kid on the block’ coming later behind the leaders.  ArcellX’s anitocabtagene autoleucel (anito-cel) is one we have been following since it was in preclinical development and were intrigued by their different scientific approach to tackling the same issues.

The big question was always going to be what happens in the clinic?

In the latest update, things are now getting interesting to say the least…

To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Posted by